Macquarie Group’s Cardiff Oncology CRDF Stock Holding History

Macquarie Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,368	Closed	-$7	–	1948
2024 Q1	$7	Buy	+1,368	New	+$3.63K	﹤0.01%	1744

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BIT Capital Berlin, Germany $3.38B AUM 214.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Macquarie Group's CRDF Position: Q2 2024 in Review

Macquarie Group sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 1,368 shares — an estimated $7 sold.

Macquarie Group first reported a position in CRDF in Q1 2024 and held it in 1 quarter. The position peaked at $7 in Q1 2024. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

Macquarie Group reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,368 Cardiff Oncology shares in Q2 2024, an estimated $7.
Macquarie Group first reported a position in Cardiff Oncology in Q1 2024 and held it in 1 quarter.
Macquarie Group's Cardiff Oncology position peaked at $7 in Q1 2024.
90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.